2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the next steps following for regorafenib (Stivarga) in colorectal cancer (CRC).
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the next steps for regorafenib (Stivarga) in colorectal cancer (CRC).
Physicians are working on confirming the results of the REVERCE study in the United States, which revealed the superiority of sequencing regorafenib before cetuximab (Erbitux) in patients with metastatic CRC who progressed on standard chemotherapy, says Bekaii-Saab.
Physicians are building a proposal asking the same question of patients with metastatic CRC that a Japanese study asked regarding the sequencing of regorafenib in a United States population. This is to better understand whether moving regorafenib to an earlier line of therapy, before EGFR inhibitors, may indeed improve outcomes—similar to what was seen in the Japanese study.